Atazanavir-Ritonavir Alone?

Although most patients who switched to this regimen maintained virologic suppression for at least 24 weeks, the long-term effectiveness of simplified therapy is not known.

Induction-maintenance trials in which HIV-infected patients switch from standard three- or four-drug therapy to two NRTIs, a PI alone, or an NRTI plus a PI have shown high virologic failure rates. In recent studies of simplification to ritonavir-boosted PIs, most patients have maintained virologic suppression, but the trials have been small, and the durability of suppression is uncertain. With once-daily dosing and few of the lipid side effects of other boosted PIs, atazanavir/ritonavir alone is an attractive possibility. How potent is this regimen?

In a multicenter, open-label study conducted by the AIDS Clinical Trials Group, 34 HIV-infected adults with virologic suppression on their first PI-containing combination antiretroviral regimen h…

Reviewing Author

Rajesh T. Gandhi, MD

Atazanavir-Ritonavir Alone?

Topics

Reviewing Author